Tri-Service General Hospital
Taipei, 114, Taiwan
Location status: Recruiting
Recruiting
NCT Number: NCT06847932
Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development
Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs > 20 beats, non-sustained AF/AFL.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Atrial Fibrillation (AF)
Arrhythmias, Cardiac
Artificial Intelligence (AI)
Atrial Arrhythmias
Atrial Fibrillation
Atrial Premature Complexes
Cardiac Complexes, Premature
Cardiac Conduction System Disease
Cardiovascular Diseases
Electrocardiogram
Heart Diseases
Pathologic Processes
Pathological Conditions, Signs and Symptoms
Premature Atrial Complexes
Age range
40 day–85 day
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients in the inpatient department or the outpatient department
- Patients need to have at least one electrocardiogram within one year
Exclusion criteria
- Diagnosis of atrial fibrillation/atrial flutter
- History of atrial fibrillation/atrial flutter catheter ablation
- Patients with cardiac implantable electronic devices
- Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
- History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
- Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant
Treatment and study plan
AF-predict AI-ECG alert system guided management
OtherAF-predict AI-ECG alert system
Primary outcomes
-
Latent atrial fibrillation
Time frame: Within 90 days after enrollment.
The primary outcome, latent atrial fibrillation, is a composite of new diagnoses of AF/AFL, atrial arrhythmia with high AF risk, including PACs ≥ 500/24hr, burst PACs > 20 beats, and non-sustained AF/AFL, within 90 days after enrollment. The results will be demonstrated as the rate of diagnoses of latent atrial fibrillation.
Secondary outcomes
-
Antiarrhythmic treatment
Time frame: Within 180 days after enrollment.
Antiarrhythmic treatment may include newly prescribed beta-blockers or non-dihydropyridine calcium channel blockers, class Ia, Ic, and III antiarrhythmic drugs, and catheter ablation. Physicians can determine whether a patient requires antiarrhythmic treatment through clinical practice. The outcome is the rate of initiation of antiarrhythmic treatment.
-
90-days New diagnoses of atrial fibrillation/atrial flutter
Time frame: Within 90 days after enrollment.
New diagnoses of atrial fibrillation or atrial flutter are defined as those documented by a 12-lead electrocardiogram or by continuous cardiac rhythm monitoring for ≥ 30 seconds. The result will be presented as the rate of new diagnoses of atrial fibrillation or atrial flutter.
-
Atrial arrhythmia with high AF risk
Time frame: Within 90 days after enrollment.
Atrial arrhythmia with high AF risk is defined by the following criteria: premature atrial complexes more than 500 beats in 24 hours as recorded by a continuous cardiac rhythm monitor; burst premature atrial complexes exceeding 20 beats as documented in a continuous cardiac rhythm monitor or a 12-lead electrocardiogram, or documented non-sustained AF/AFL in either a continuous cardiac rhythm monitor or a 12-lead electrocardiogram. The result will be presented as the rate of diagnoses of atrial arrhythmia with high AF risk.
Study contacts
Contact information is provided by the study sponsor or research team.
ChiaoChin Lee, MD
CONTACT
Chin Lin, PhD
CONTACT
+886-2-8792-3100 Ext. 18574
Sponsors and collaborators
Lead sponsor
National Defense Medical Center, Taiwan
Other
Registry information
Official study title
Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development: a Randomized Control Trial
Acronym: LATENT
Important dates
- Study start
- 2025
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Feb 26, 2025
- Registry last updated
- Nov 19, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Disrupted Sleep and Concurrent Ectopy or Atrial Fibrillation
NCT07220525
Apnea, Arrhythmias, Cardiac
San Francisco, California, United States
View Trial Details
Recruiting
Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System
NCT07018648
Arrhythmias, Cardiac, Atrial Fibrillation
Olomouc, Czechia
View Trial Details
Recruiting
Concurrent Training in Patients Undergoing Atrial Fibrillation Ablation.
NCT06832033
Arrhythmias, Cardiac, Atrial Fibrillation
Zaragoza, Spain
View Trial Details
Not Yet Recruiting
throMboembolic Risk Associated To High atrIal Fibrillation riSk
NCT07441759
Arrhythmias, Cardiac, Artificial Intelligence (AI)
Tortosa, Tarragona, Spain
View Trial Details